Guidelines

AAN issues nonvalvular atrial fibrillation stroke prevention guideline

View on the News

'Tepid guidelines' miss opportunity


Dr. Richard Bernstein

These guidelines are a missed opportunity to empower neurologists to advocate in favor of anticoagulation to prevent stroke. The biggest public health problem in AF is that only half of patients who need anticoagulation are getting it. This disgraceful state of affairs results in patients having cardioembolic strokes that are fatal or worse and that could have been prevented. We neurologists see these complications of inadequate treatment and should be on the front lines of prevention. These tepid guidelines give as much space to bleeding as they do to ischemic stroke prevention, which is inappropriate, and I fear will make neurologists, who are not terribly assertive under any circumstances, even less willing to push doctors to use anticoagulants.

I would have been happier with a single page that said: "Stop using aspirin. Patients fear major stroke more than they fear bleeding or death, and they are right. Stop undertreating your patients and start preventing strokes."

Dr. Richard A. Bernstein is professor of neurology and director of the stroke program at Northwestern University, Chicago.


 

FROM NEUROLOGY

A new evidence-based guideline on how to identify and treat patients with nonvalvular atrial fibrillation to prevent cardioembolic stroke from the American Academy of Neurology suggests when to conduct cardiac rhythm monitoring and offer anticoagulation, including newer agents in place of warfarin.

But the guideline might already be outdated in not considering the results of the recent CRYSTAL-AF study, in which long-term cardiac rhythm monitoring of patients with a previous cryptogenic stroke detected asymptomatic patients at a significantly higher rate than did standard monitoring methods.

Dr. Antonio Culebras

The guideline also extends the routine use of anticoagulation for patients with nonvalvular atrial fibrillation (NVAF) who are generally undertreated or whose health was thought a possible barrier to their use, such as those aged 75 years or older, those with mild dementia, and those at moderate risk of falls.

"Cognizant of the global reach of the AAN [American Academy of Neurology], the guideline also examines the evidence base for a treatment alternative to warfarin or its analogues for patients in developing countries who may not have access to the new oral anticoagulants," said lead author Dr. Antonio Culebras in an interview.

"The World Health Organization has determined that atrial fibrillation has reached near-epidemic proportions," observed Dr. Culebras of the State University of New York, Syracuse. "Approximately 1 in 20 individuals with AF will have a stroke unless treated appropriately."

The risk for stroke among patients with NVAF is highest in those with a history of transient ischemic attack (TIA) or prior stroke, at an absolute value of around 10% per year. Patients with "lone NVAF," meaning they have no additional risk factors, have less than a 2% increased risk of stroke per year.

The AAN issued a practice parameter on this topic in 1998 (Neurology 1998;51:671-3). At the time, warfarin, adjusted to an international normalized ratio (INR) of 2.0, was, and largely remains, the recommended standard for patients at risk for cardioembolic stroke. Aspirin was the only recommended alterative for those unable to receive the vitamin K antagonist or who were deemed to be at low risk of stroke, although the evidence was scanty.

Since then, several new oral anticoagulant agents have become available, including the direct thrombin inhibitor dabigatran (Pradaxa), and two factor Xa inhibitors – rivaroxaban (Xarelto) and apixaban (Eliquis) – which have been shown to be at least as effective as, if not more effective than, warfarin. Cardiac rhythm monitoring via a variety of methods has also been introduced as a means to try to detect NVAF in asymptomatic patients.

The aim of the AAN guideline (Neurology 2014;82:716-24) was therefore to look at the latest evidence on the detection of AF using new technologies, as well as the use of treatments to reduce the risk of stroke without increasing the risk of hemorrhage versus the long-standing standard of therapy, warfarin. Data published from 1998 to March 2013 were considered in the preparation of the guideline.

Cardiac rhythm monitoring for NVAF

Seventeen studies were found that examined the use of cardiac monitoring technologies to detect new cases of NVAF. The most common methods used were 24-hour Holter monitoring and serial electrocardiograms, but some emerging evidence on newer technologies was included. The proportion of patients identified with NVAF ranged from 0% to 23%, with the average detection rate 10.7% in all of the studies included.

"The guideline addresses the question of long-term monitoring of patients with NVAF," Dr. Culebras said. "It recommends that clinicians ‘might’ [level C evidence] obtain outpatient cardiac rhythm studies in patients with cryptogenic stroke without known NVAF to identify patients with occult NVAF." He added that the guideline also recommends that monitoring might be needed for prolonged periods of 1 or more weeks rather than for shorter periods, such as 24 hours.

However, at the time the guideline was being prepared, recent data from the CRYSTAL-AF study were not available, and this means the guideline is already outdated, Dr. Richard A. Bernstein, professor of neurology at Northwestern University, Chicago, said in an interview. He was not a guideline author.

Dr. Bernstein was on the steering committee for the CRYSTAL-AF trial, which assessed the performance of Medtronic’s Reveal XT Insertable Cardiac Monitor and found that the implanted device could detect NVAF better than serial ECGs or Holter monitoring (8.6% vs. 1.4%; P = .0006); most (74%) cases of NVAF found were asymptomatic.*

"CRYSTAL-AF represents the state of the art for cardiac monitoring in cryptogenic stroke patients and makes the AAN guidelines obsolete," Dr. Berstein said. "[The study] shows that even intermediate-term monitoring (less than 1 month) will miss the majority of AF in this population, and that most of the AF we find with long-term (greater than 1 year) monitoring is likely to be clinically significant."

Pages

Recommended Reading

Low event rates with real-world use of rivaroxaban in NOAC
MDedge Family Medicine
CRT shown highly cost effective in mild heart failure
MDedge Family Medicine
FDA panel rejects rivaroxaban again for acute coronary syndrome
MDedge Family Medicine
Personalization keys vision of improved atrial fib care
MDedge Family Medicine
Cooling the resuscitated sudden dead
MDedge Family Medicine
CoreValve holds size advantage for U.S. TAVR
MDedge Family Medicine
New tools for stroke prediction in atrial fibrillation
MDedge Family Medicine
Ablation edges out drugs for treatment-naive paroxysmal atrial fibrillation
MDedge Family Medicine
VIDEO: Device detects more atrial fibrillation, but when is intervention necessary?
MDedge Family Medicine
Continuous AF monitors raise questions about when to intervene
MDedge Family Medicine